Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc., trading under the ticker CDIO on Nasdaq, is an AI-powered cardiovascular disease diagnostics company that completed its SPAC merger with Mana Capital Acquisition Corp in late 2022, with Mana Capital LLC serving as sponsor on the original 2021 SPAC IPO. The company focuses on epigenetics-based diagnostic tests designed to detect and predict cardiovascular disease, operating within the healthcare and molecular diagnostics sector. In November 2024, the company filed an 8-K with the SEC, continuing its post-merger public reporting obligations. CDIO remains an actively traded post-combination company in the cardiovascular health technology space. Sign up at SpacDesk for full filing history, sponsor profiles, and real-time SPAC data on CDIO and hundreds of other deals.